Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next three days.
In the meantime, you can enjoy access to all the latest news, events and resources for different therapy areas on our website.
Why choose BOOSTRIX to vaccinate against pertussis during pregnancy?
BOOSTRIX is the first Tdap vaccine to include prospective safety data* in pregnant women in its label. 1-6
New data from a phase IV clinical trial on the safety and immunogenicity of BOOSTRIX use during the 3rd trimester of pregnancy 8
Indications
Boostrix is indicated for booster vaccination against diphtheria, tetanus and pertussis of individuals from the age of four years onwards
The administration of Boostrix should be based on official recommendations.
Dosage
A single 0.5 ml dose of the vaccine is recommended.
Boostrix may be administered from the age of four years onwards.
The use of Boostrix may be considered during the third trimester of pregnancy
Boostrix can be used in the management of tetanus prone injuries in persons who have previously received a primary vaccination series of tetanus toxoid vaccine and for whom a booster against diphtheria and pertussis is indicated. Tetanus immunoglobulin should be administered concomitantly in accordance with official recommendations.1
Tdap: tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine, adsorbed.
* The benefit versus the risks of administering BOOSTRIX during pregnancy should be carefully evaluated. 1
† Limited data indicate that maternal antibodies may reduce the magnitude of the immune response to some vaccines in infants born from mothers vaccinated with a Tdap vaccine during pregnancy; this phenomenon is known as blunting. The clinical relevance of this observation is unknown. 7
References:
- Local Boostrix Prescribing Information based on GDS 14. GlaxoSmithKline Biologicals. BOOSTRIX-IPV SmPC, January 2019. [accessed May 2019]; Available at: https://www.medicines.org.uk/emc/product/5302/smpc
- Sanofi Pasteur MSD Ltd. Triaxis (Adacel) SmPC, 2019. [accessed May 2019];Available at https://www.hpra.ie/img/uploaded/swedocuments/Final%20approved%20SPC%20PA2131-010-002.pdf
- Sanofi Pasteur MSD Ltd. Repevax suspension for injection SmPC, 2019. [accessed May 2019]; Available at https://www.hpra.ie/img/uploaded/swedocuments/Final%20approved%20SPC%20PA2131-006-001.pdf
- AJ Vaccines. diTeki SmPC. [accessed May 2019]; Available at: https://mri.cts-mrp.eu/Human/Downloads/DK_H_0143_002_FinalSPC.pdf
- Sanofi Pasteur MSD Ltd. Triaxis (Adacel) SmPC, 2018.
- Sanofi Pasteur MSD Ltd. Repevax suspension for injection SmPC, 2018.
- Gkentzi D, et al. Maternal vaccination against pertussis: a systematic review of the recent Literature. Arch Dis Child Fetal Neonatal ed. 2017;102(5):F456-F643.
- Perrett K, et al. Pertussis vaccination during pregnancy: a multi-country randomised placebo-controlled trial assessing immunogenicity and safety of dTpa in mothers and their infants. Poster presented at RCOG, June 17–19, 2019, London, UK.
All mentioned products are registered in Saudi Arabia. This page may contain promotional content. For full prescribing information or adverse events reporting, please click on the relevant button in the header or footer of this page.
Trade marks are owned by or licensed to the GSK group of companies.
©2021 GSK group of companies or its licensor.
